Nurse Practitioner in Riverdale, CA Accepting Medicare
4 Nurse Practitioner nurses found. Showing 1 - 4
 David Davis, FNP Nurse Practitioner - Family Medicare: Medicare Enrolled Practice Location: 3554 W Mt Whitney, Riverdale, CA 93656 Phone: 559-867-4000 Fax: 559-867-1100 |
 Michelle Carter-murphy, F.N.P. Nurse Practitioner - Family Medicare: Medicare Enrolled Practice Location: 3567 W. Mt. Whitney Ave., Riverdale, CA 93656 Phone: 559-867-4416 Fax: 559-867-6002 |
Mandeep Kaur Sidhu, NP Nurse Practitioner - Family Medicare: Medicare Enrolled Practice Location: 3554 W Mt Whitney, Riverdale, CA 93656 Phone: 559-867-4000 Fax: 559-867-1100 |
Gurinder Kaur, MSN, FNP-C Nurse Practitioner - Family Medicare: Medicare Enrolled Practice Location: 3567 Mt Whitney Ave., Riverdale, CA 93656 Phone: 559-867-7200 Fax: 559-867-0152 |
News Archive
Hypertension drug market to decrease through 2013 due to generic erosion and few emerging therapies
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in addition to extensive generic erosion, the hypertension drug market will be constrained through 2018 by a pipeline containing very few emerging therapies with novel mechanisms of action. Gilead's darusentan was positioned to be the next emerging therapy with a novel mechanism of action to reach the hypertension market. However, following darusentan's failure to meet its primary endpoint in the recent DORADO-AC Phase III clinical trial, further development of the agent has been terminated.
Cases of meningitis caused by herpes simplex virus set to rise
Viral meningitis is common, but many cases go unreported, say researchers in this week's BMJ.
Dacogen data presented on trial in seniors with acute myeloid leukemia
Eisai Corporation of North America has announced data from a Phase II trial evaluating a five-day dosing regimen of Dacogen(R) (decitabine for injection) in acute myeloid leukemia (AML), the most common form of leukemia.
NCI awards Soligenix $300,000 SBIR grant for orBec Phase 2 chronic GI GVHD trial
Soligenix, Inc., a development stage biopharmaceutical company, announced today that the National Cancer Institute has awarded Soligenix a Small Business Innovation Research grant to support the conduct of a Phase 2 clinical trial designed to evaluate orBec (oral beclomethasone 17,21-dipropionate or BDP) as a treatment for the gastrointestinal manifestation of chronic Graft-versus-Host disease.
› Verified 8 days ago
Nurse Practitioner
Physician Assistant
Registered Nurse
Licensed Vocational Nurse